Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
NCT ID: NCT05526443
Last Updated: 2025-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1500 participants
OBSERVATIONAL
2023-01-13
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tumor Registry Pancreatic Cancer
NCT02089269
Treatment of Pancreatic Cancer With Abraxane
NCT02555813
Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
NCT02125136
Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature
NCT05314998
PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma
NCT04099134
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient with locally advanced inoperable and/or metastatic pancreatic ductal adenocarcinoma
Patient with locally advanced inoperable and/or metastatic pancreatic ductal adenocarcinoma
all approved chemotherapeutic agents from second line
all approved chemotherapeutic agents from second line
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
all approved chemotherapeutic agents from second line
all approved chemotherapeutic agents from second line
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ECOG (Eastern Cooperative Oncology Group) Scale 0-2
* Diagnosis of histologically confirmed locally advanced inoperable and/or metastatic PDAC
* Patients undergoing palliative 1st line therapy with a platinum- or gemcitabine- based chemotherapy in case of previous (neo)adjuvant therapy also patients who receive nal-Irinotecan/5-FU/Leukovorin as palliative first line are eglible
* Signed informed consent for prospective patients, for retrospective cases no informed consent is required
Exclusion Criteria
* Patients with locally advanced borderline resectable PDAC who do not receive palliative chemotherapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Graz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jakob Riedl, Priv.Doz. Dr.
Role: PRINCIPAL_INVESTIGATOR
Medical University of Graz
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University Graz Department of Oncology
Graz, Styria, Austria
Ordensklinikum Linz
Linz, Upper Austria, Austria
Landesklinikum Amstetten
Amstetten, , Austria
Landesklinikum Feldkirch
Feldkirch, , Austria
Krankenhaus der Barmherzigen Brüder
Graz, , Austria
Universitätsklinikum Innsbruck,
Innsbruck, , Austria
Landesklinikum Klagenfurt
Klagenfurt, , Austria
Universitätsklinikum St. Pölten
Sankt Pölten, , Austria
Barmherzige Schwestern Krankenhaus Wien
Vienna, , Austria
Pancreatic Cancer Unit des Comprehensive Cancer Center (CCC-PCU)
Vienna, , Austria
St. Josef Krankenhaus Wien
Vienna, , Austria
Krankenhaus St. Vinzenz Zams
Zams, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Daniel Mayer, Dr.
Role: primary
Role: backup
Wolfgang Eisterer, Univ. Prof. Dr.
Role: primary
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ADPACA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.